Search the Journal

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Read Full Text


Download PDF


View Table of Contents

S100 Proteins Calprotectin and S100A12 Are Related to Radiographic Changes Rather Than Disease Activity in Psoriatic Arthritis with Low Disease Activity

TOR MAGNE MADLAND, ANNETTE LARSEN, and JOHAN G. BRUN

ABSTRACT.

Objective.
To investigate serum levels of calprotectin (S100A8/S100A9) and S100A12 as markers of disease activity or distinct clinical or radiographic features in patients with psoriatic arthritis (PsA).

Methods. Serum levels of calprotectin and S100A12, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were determined in 119 patients with PsA. Correlations to clinical variables were calculated, and subgroups of patients were compared.

Results. The correlations to clinical disease activity measures were stronger for CRP than for ESR and calprotectin. In the regression analysis, calprotectin was identified as an independently associated factor for presence of peripheral radiographic features of arthritis (OR 1.33, 95% CI 1.01–1.76). S100A12 levels were also elevated in those with peripheral radiographic features (p = 0.036), but did not correlate with clinical variables of disease activity.

Conclusion. Calprotectin and S100A12 do not perform better than traditional biomarkers of disease activity in PsA, but were associated with presence of peripheral radiographic features in this cross-sectional study. The patients' low level of disease activity may have led to underestimation of the associations between any biomarker and disease measures. (First Release Sept 1 2007; J Rheumatol 2007;34:2089-92)

Key Indexing Terms:

PSORIATIC ARTHRITIS
CALPROTECTIN
S100A8/S100A9
S100A12
BIOMARKERS


From the Section for Rheumatology and Section for Oncology, Institute of Medicine, University of Bergen, and Department of Rheumatology and Department of Oncology, Haukeland University Hospital, Bergen, Norway.

Supported in part by a grant from the Norwegian Women's Public Health Association.

T.M. Madland, MD; J.G. Brun, MD, PhD, Professor, Section for Rheumatology, Institute of Medicine, University of Bergen, and Department of Rheumatology, Haukeland University Hospital; A. Larsen, MD, PhD, Section for Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital.

Address reprint requests to Dr. T.M. Madland, Department of Rheumatology, Haukeland University Hospital, N-5021 Bergen, Norway. E-mail: tor.madland@helse-bergen.no

Accepted for publication June 21, 2007.




Return to September 2007 Table of Contents



© 2007. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.